With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1197-66-6,2,2,6,6-Tetramethyl-2H-3,5,6-trihydropyran-4-one,as a common compound, the synthetic route is as follows.
4,4,6,6-Tetramethyl-4H,6H,7H-pyrano[4,3-d] [l,3]thiazol-2-amine A solution of 2,2,6,6-tetramethyloxan-4-one (250 mg,l .60 mmol), pyrrolidine (125 mg, 1.76 mmol) andpTSA (15 mg, 0.08 mmol) in cyclohexane (2 mL) was refiuxed for 2 h. The solvent was removed and replaced by MeOH (0.5 mL) and then sulfur was added (51 mg, 0.20 mmol) followed by cyanamide (74 mg, 1.76 mmol). The solution was refiuxed for 2 h, cooled, diluted with EtOAc and filtered. The filtrate was adsorbed onto silica gel and purified by FCC (eluent: EtOAc: Heptane (0-100%) to afford the title compound as a yellow solid (210 mg, 62% yield); m/z = 213.0 (MH)+.
1197-66-6, The synthetic route of 1197-66-6 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; ACTIVE BIOTECH AB; WELLMAR, Ulf; EAST, Stephen; BAINBRIDGE, Marie; MACKINNON, Colin; CARR, James; HARGRAVE, Jonathan; (296 pag.)WO2016/42172; (2016); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics